Last 13,200 KRW
Change Today -100.00 / -0.75%
Volume 442.0K
085660 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 11:12 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

chabiotech co ltd (085660) Snapshot

Open
13,350
Previous Close
13,300
Day High
13,500
Day Low
13,100
52 Week High
06/2/14 - 19,400
52 Week Low
11/11/13 - 10,955
Market Cap
665.2B
Average Volume 10 Days
1.6M
EPS TTM
350.81
Shares Outstanding
50.2M
EX-Date
12/29/09
P/E TM
37.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHABIOTECH CO LTD (085660)

Related News

No related news articles were found.

chabiotech co ltd (085660) Related Businessweek News

No Related Businessweek News Found

chabiotech co ltd (085660) Details

CHA Bio&Diostech Inc. provides optical, bio medicine, and health care solutions in South Korea. It offers optical products, including mobile, automobile, CCTV, and functional lens modules, as well as actuators; Bluetooth products, such as wireless earphones and headsets; and vehicle black box products. The company also provides Hyalograft 3D for diabetic foot ulcers; Autostem, a cell therapy for subcutaneous fat loss area; LSK Autograft, a cell therapy for burns; medical devices, such as anti-adhesion agents and plastic fillers; and Protein Bio Similar for GM-CSF and growth factors. In addition, it offers drug dispersions on water soluble films; drugs for infants, elderly, and patients; and weaning and elderly diets, maternal health foods, and prepared meals. Further, the company provides medical supply development services comprising development strategy consultation, clinical trials, permit registration, and post-market surveys; personalized health information; bio insurance, bio cosmetics/beauty, stem cell technology and therapeutics, and health assessment services; and medical treatment and anti aging care services. Additionally, it offers integrated medical services, including advertising marketing, and medical consultation and appointment agency services; and homepage and health care contents development and management, brand management, design service, and publishing services, as well as online and printed media PR and ads. The company also offers IT services, such as health information R and D, HIS and U-health service development and operation, maintenance repair and operation, computer equipment purchasing agency, and maintenance and repair services; operates Cha the Shop and Bau&bebe that are specialty shops for luxury infant wear, children’s wear, and maternity dresses; sells baby gifts and infant education products; and manages a special infant and children’s shopping mall. CHA Bio&Diostech Inc. was founded in 2000 and is based in Seoul, South Korea.

Founded in 2000

chabiotech co ltd (085660) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

chabiotech co ltd (085660) Key Developments

CHA Bio & Diostech Co., Ltd., Annual General Meeting, Mar 31, 2014

CHA Bio & Diostech Co., Ltd., Annual General Meeting, Mar 31, 2014., at 11:00 Korea Standard Time. Location: Yongin 113-12 namsamyeon cheoingu Co. auditorium. Agenda: To consider the approval of the financial statements and connections for the year ended Dec. 31, 2013; to consider the approval of the division plan; to consider the appointment of director; to consider the appointment of corporate directors; to consider the appointment of auditors; to consider the approval of director remuneration; and to consider other references concerning investment decisions.

Cha Bio&Diostech Files Investigational New Drug with Korean FDA for PLX Cells

On the heels of announcing its strategic partnership agreement with Cha Bio&Diostech on June 26, Pluristem Therapeutics Inc. announced today that Cha Bio&Diostech has filed its first investigational new drug (IND) application for Pluristem's PLacental eXpanded (PLX) cells with the Korean Food and Drug Administration (KFDA). This IND is for the use of PLX-PAD in the treatment of intermittent claudication (IC) and mirrors the clinical protocol implemented by Pluristem in its FDA supervised Phase II IC clinical trial in the United States. Pluristem recently announced that under the terms of its agreement with Cha, Cha will perform and fund multiple clinical trials in South Korea for treating critical limb ischemia (CLI) and IC using PLX-PAD under the supervision of the KFDA. Upon the first regulatory approval for a PLX product in South Korea, Pluristem and Cha will establish a joint venture (JV) co-owned by the parties. The purpose of the JV will be to commercialize PLX cell products in South Korea.

Pluristem Therapeutics, Inc. Enters into Exclusive License and Commercialization Agreement with CHA Bio & Diostech Co., Ltd

On June 26, 2013, a wholly owned subsidiary of Pluristem Therapeutics, Inc. entered into an Exclusive License and Commercialization Agreement with CHA Bio & Diostech Co., Ltd. for conducting clinical trials and commercialization of Pluristem's PLX-PAD product in South Korea in connection with two indications: the treatment of Critical Limb Ischemia, and Intermediate Claudication (collectively, the Indications). Under the terms of the Agreement, CHA will receive exclusive rights in South Korea for conducting clinical trials with respect to the Indications, at the sole expense of CHA. Commencement of the clinical trials is conditioned upon the receipt of the necessary regulatory approvals. If Pluristem's products receive regulatory approvals in South Korea for marketing as treatment for the Indications, the parties will form a joint venture in order to sell, distribute and market Pluristem products for treating the Indications in South Korea. The joint venture would be owned equally by CHA and Pluristem. Pluristem would own any and all intellectual property rights to the extent conceived in connection with its products and license such rights to the joint venture.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
085660:KS 13,200.00 KRW -100.00

085660 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 085660.
View Industry Companies
 

Industry Analysis

085660

Industry Average

Valuation 085660 Industry Range
Price/Earnings 41.7x
Price/Sales 1.4x
Price/Book 2.4x
Price/Cash Flow 41.9x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHABIOTECH CO LTD, please visit www.chabio.co.kr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.